Literature DB >> 18698556

Characterization of saccharides and phenolic acids in the Chinese herb Tanshen by ESI-FT-ICR-MS and HPLC.

Huilin Li1, Fengrui Song, Zhong Zheng, Zhiqiang Liu, Shuying Liu.   

Abstract

This study sought to determine the main components (saccharides and phenolic acids) in crude extract of the Chinese herb Tanshen by electrospray ionization Fourier transform ion cyclotron resonant mass spectrometry (ESI-FT-ICR-MS) in negative-ion mode. Eleven compounds were identified as phenolic acids by exact mass measurement and further confirmed by sustained off-resonance irradiation (SORI) CID data. In addition, monosaccharides and oligosaccharides (n = 2-5) and a serial of corresponding anionic adducts of saccharide were observed without adding any anions additionally to the extract solution, and the anionic components were unambiguously identified as H2O, HCl, HCOOH, HNO3, C3H6O2, H2SO4 and C5H7NO3 according to the exact mass measurement results. Furthermore, the saccharide types in Tanshen extract were identified as raffitrinose, saccharose, glucose, galactose and fructose with HPLC by comparing standards.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18698556     DOI: 10.1002/jms.1441

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  3 in total

1.  Application of quality by design to the process development of botanical drug products: a case study.

Authors:  Lei Zhang; Binjun Yan; Xingchu Gong; Lawrence X Yu; Haibin Qu
Journal:  AAPS PharmSciTech       Date:  2013-01-08       Impact factor: 3.246

2.  Design space development for the extraction process of Danhong injection using a Monte Carlo simulation method.

Authors:  Xingchu Gong; Yao Li; Huali Chen; Haibin Qu
Journal:  PLoS One       Date:  2015-05-28       Impact factor: 3.240

Review 3.  An update on oligosaccharides and their esters from traditional chinese medicines: chemical structures and biological activities.

Authors:  Xiang-Yang Chen; Ru-Feng Wang; Bin Liu
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-15       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.